Top

Published in:

01-12-2008 | Original Article

Clinicopathological characteristics of erythroblast-rich RAEB and AML M6a in children

Authors: Yuko Honda, Atsushi Manabe, Masahiro Tsuchida, Yuji Zaike, Atsuko Masunaga, Masami Inoue, Ryoji Kobayashi, Yoshitoshi Ohtsuka, Akira Kikuchi, Tatsutoshi Nakahata, From the MDS Committee, the Japanese Society of Pediatric Hematology

Published in: International Journal of Hematology | Issue 5/2008

Abstract

The distinction between RAEB, RAEB-T and AML M6a is difficult when erythroblasts in the bone marrow (BM) exceed 50%. We analyzed 19 children (2 RAEB, 13 RAEB-T and 4 AML M6a) enrolled in a prospective pathological central review in Japan and divided them into two groups according to the myeloblasts percentage among non-erythroid cells in BM: group A (n = 8), 5–19% myeloblasts; group B (n = 11), 20% or more myeloblasts. Their characteristics were very similar except for the number of myeloblasts. The median WBC was in the range of 1.0–5.0 × 10⁹ L⁻¹, the median Hb was around 7.5 g/dL, the median MCV was greater than 90 fL and both group had Auer rods at 60–65%. Severe multilineage dysplasia was observed in most of the patients in two groups. Six with group A and seven with group B treated with AML type chemotherapy achieved complete remission. Five with group A and seven with group B undergoing SCT are alive at a median of 3 years after diagnosis. Erythroblast-rich RAEB and AML M6a in children have similar characteristics and may belong to a single disease entity.

Bennett JM, Catovsky D, Daniei MT, Flandrin G, Galton DAG, Garlnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–99.CrossRefPubMed

Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J. The World Health Organization Classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol. 1999;10:1419–32. doi:10.1023/A:1008375931236.CrossRefPubMed

Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kendrup G, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative disease. Leukemia. 2003;17:277–82. doi:10.1038/sj.leu.2402765.CrossRefPubMed

Rosati S, Anastasi J, Vardiman J. Recurring diagnostic problems in the pathology of the myelodysplastic syndromes. Semin Hematol. 1996;33:111–26.PubMed

Passmore SJ, Chessells JM, Kempski H, Hann I, Brownbill PA, Stiller CA. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population-based study of incidence and survival. Br J Haematol. 2003;121:758–67. doi:10.1046/j.1365-2141.2003.04361.x.CrossRefPubMed

Sasaki H, Manabe A, Kojima S, Tsuchida M, Hayashi Y, Ikuta K, et al. Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan. Leukemia. 2001;15:1713–20.CrossRefPubMed

Manabe A. Recent progress in childhood myelodysplastic syndrome. Japan J Pediatr Hematol. 2007;21:141–51. (in Japanese).

Manabe A, Kojima S. Eleventh symposium on aplastic anemia and 9th symposium on myelodysplastic syndrome in children. Pediatr Int. 2005;47:572–4. doi:10.1111/j.1442-200x.2005.02122.x.CrossRefPubMed

Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–25. doi:10.1182/blood-2005-10-4149.CrossRefPubMed

10.

Strupp C, Gattermann N, Giagounidis A, Giagounidis A, Aul C, Hildebrandt B, et al. Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals. Leuk Res. 2003;27:397–404. doi:10.1016/S0145-2126(02)00220-5.CrossRefPubMed

11.

Willis MS, Mckenna RW, Peterson LC, Coad JE, Kroft SH. Low blast count myeloid disorders with Auer rods: a clinicopathologic analysis of 9 cases. Am. J. Clin. Pathol. 2005;124:191–8. doi:10.1309/WB79MFV6FCDJH2EG.CrossRefPubMed

12.

Webb DKH, Harrison G, Stevens RF, Gibson BG, Hann I, Wheatley K. Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood. 2001;98:1714–20. doi:10.1182/blood.V98.6.1714.CrossRefPubMed

13.

Barnard DR, Alonzo TA, Gerbing RB, Lange B, Woods WG. Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the children’s oncology group. Pediatr Blood Cancer. 2007;49:17–22. doi:10.1002/pbc.20951.CrossRefPubMed

14.

Niemeyer C, Duffner U, Bender-Gotze C, et al. AML-intensive chemotherapy prior to stem cell transplantation (SCT) does not improve survival in children and adolescents with primary myelodysplastic sundrome (MDS). Blood. 2000;96(Suppl 1):521a. abstract.

15.

Webb DK, Passmore SJ, Hann IM, Harrison G, Wheatley K, Chessells J. Results of treatment of children with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEBt) in Great Britain 1990–99. Br J Haematol. 2002;117:33–9. doi:10.1046/j.1365-2141.2002.03369.x.CrossRefPubMed

16.

Park S, Picard F, Dreyfus F. Erythroleukemia: a need for a new definition. Leukemia. 2002;16:1399–401. doi:10.1038/sj.leu.2402549.CrossRefPubMed

17.

Park S, Picard F, Azgui Z, Viguie F, Merlat A, Guesnu M, et al. Erythroleukemia: a comparison between the previous FAB approach and the WHO classification. Leuk Res. 2002;26:423–9.CrossRefPubMed

Title: Clinicopathological characteristics of erythroblast-rich RAEB and AML M6a in children
Authors: Yuko Honda
Atsushi Manabe
Masahiro Tsuchida
Yuji Zaike
Atsuko Masunaga
Masami Inoue
Ryoji Kobayashi
Yoshitoshi Ohtsuka
Akira Kikuchi
Tatsutoshi Nakahata
From the MDS Committee, the Japanese Society of Pediatric Hematology
Publication date: 01-12-2008
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 5/2008
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-008-0183-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2008

Phase II open label trial of imatinib in polycythemia rubra vera

Establishment of CD5 and CD10 double-positive mature B-cell line, WILL1, showing complex 8q24 translocation involving 14q32 and 6q27

Advanced mast cell disease: an Italian Hematological Multicenter experience

Post-transplant plasmacytoma without Epstein–Barr virus infection occurring rapidly after unrelated allogeneic bone marrow transplantation

Renal vein lymphoma embolism in non-Hodgkin lymphoma

Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer